Jeffrey Wolf, MD

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.

Wolf touched on the future of MRD and the potential development of more sensitive measuring techniques for patients with multiple myeloma.

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.